Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use
Section snippets
A Pathophysiologic Perspective
Progressive impairment of β-cell function and increased insulin demand as tissue becomes insulin resistant are core pathophysiologic defects in the development and progression of hyperglycemia in type 2 diabetes.1, 2 However, other important factors are also known to further exacerbate this pathology. Excess glucagon secretion, abnormal gastric emptying during hyperglycemia, obesity, and increased food intake all contribute to, or worsen, hyperglycemia in type 2 diabetes. Impaired release or
Incretin-Based Therapy: A Clinical Perspective
Traditional treatment strategies for type 2 diabetes use single therapies, often added in a sequential fashion. As additional therapies are added only when specific treatment targets are not achieved, this “failure-based” approach often results in a delay in advancing therapy.4, 5, 6 Current treatment recommendations for the management of type 2 diabetes advise lifestyle changes—moderate weight loss (5% to 10%) and physical activity for ≥30 minutes per day.7, 8 If appropriate, metformin is
Current Clinical Challenges in the Treatment of Diabetes Mellitus
The vast majority of patients with type 2 diabetes currently are treated with ≥1 oral hypoglycemic agent—with increasing numbers of patients now using insulin (most commonly basal insulin) earlier in the course of treatment. Despite the introduction of several new classes of antidiabetic agents in the United States and worldwide between 1995 and 2004, slightly >50% of patients with type 2 diabetes achieve HbA1c values ≤7% (the current community standard advised by the American Diabetes
A Pathophysiologic Perspective: The Natural History of Type 2 Diabetes Mellitus
Intelligent use of antidiabetic drugs is critically dependent on a sound understanding of the natural history of diabetes and of the underlying pathophysiologic defects that give rise to the disease. Type 2 diabetes is a complex metabolic disorder characterized by elevated blood glucose and a marked increase in the risk of cardiovascular disease. The increase in cardiovascular disease risk is a consequence of a cluster of metabolic and vascular abnormalities including hyperglycemia,
Clinical Application of Incretin-Based Treatments
Both GLP-1 receptor agonists and the DPP-4 inhibitors seek to leverage the pharmacologic effects of incretin hormones. Incretin-based agents provide clinicians with new interventional strategies for the improvement of fasting and postmeal glucose, islet function, and body weight.
Use of Incretin-Based Therapies: A Pathophysiologic Perspective
Currently, metformin is widely recommended as the initial therapy of choice for patients with type 2 diabetes. Metformin is commonly used in combination with lifestyle interventions as the first step in treatment or as add-on therapy if patients are unable to achieve or maintain adequate glycemic control (HbA1c ≤7%) with diet and exercise alone. Figure 338, 39, 40, 41, 42, 43, 44, 45, 46, 47 describes an approach to therapy selection based on the level of glycemic control at presentation, while
Clinical Comparison of DPP-4 Inhibitors and GLP-1 Receptor Agonists
Table 1 provides a summary of the clinical effects of both GLP-1 receptor agonists and DPP-4 inhibitors. Although the list of effects is not exhaustive, it should help clinicians quickly identify the potential role for each of these therapies. Both classes of drug work well in combination with other diabetes therapies, although efficacy may be greater with GLP-1 receptor agonists. Both classes differ in route of administration and may have differing side effect and tolerability profiles. Thus
Clinical Use of Incretin Based Therapy: A Practical Summary
Effective therapies for diabetes exist, but therapies that are even more effective, safer, and more durable in their ability to control glycemia are clearly needed. Incretin-based therapies are among the more recent attempts to meet those needs. The appropriate use of such therapies should assist the clinician in addressing the progressive nature of type 2 diabetes—not only preventing deterioration in glucose control but also the weight increase commonly observed in this disease and often
Author Disclosures
The authors who contributed to this article have disclosed the following industry relationships:
David M. Kendall, MD, has worked as a consultant to Amylin Pharmaceuticals, Inc., Daiichi-Sankyo Co. Ltd., Eli Lilly & Co., HealthPartners, Intarcia Therapeutics, Inc., Nektar Therapeutics, and Takeda Pharmaceuticals North America, Inc; has served on scientific/clinical advisory boards for Amylin Pharmaceuticals, Inc., Daiichi-Sankyo Co. Ltd., Eli Lilly & Co., HealthPartners, Intarcia Therapeutics,
Acknowledgment
We thank AdelphiEden for providing editorial services.
References (129)
Unraveling the science of incretin biology
Am J Med
(2009)- et al.
Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus
Am J Med
(2009) Treatment models from the International Diabetes Center: advancing from oral agents to insulin therapy in type 2 diabetes
Endocr Pract
(2006)- et al.
Incretin therapies: effects beyond glycemic control
Am J Med
(2009) - et al.
Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes
Regul Pept
(2004) - et al.
Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial
Clin Ther
(2007) - et al.
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Lancet
(2008) - et al.
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
Lancet
(2009) - et al.
Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin
Endocr Pract
(2007) - et al.
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
Clin Ther
(2007)
The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus
J Clin Invest
The fate of Beta-cells in type 2 diabetes and the possible role of pharmacological interventions
Rev Diabet Stud
Reinventing type 2 diabetes: pathogenesis, treatment, and prevention
JAMA
Glycemic response to newly initiated diabetes therapies
Am J Manag Care
Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycemic goals in patients with Type 2 diabetes in UK primary care
Diabet Med
Loss of confidence in diabetes management
Manag Care
Metformin & lifestyle intervention prevent Type 2 diabetes: lifestyle intervention has the greater effect
Expert Opin Pharmacother
Diabetes control with physical activity and exercise
Nutr Clin Care
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapyA consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
Diabetes Care
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
Lancet
Oral antihyperglycemic therapy for type 2 diabetes: scientific review
JAMA
The barrier of hypoglycemia in diabetes
Diabetes
Unmet needs among patients with type 2 diabetes and secondary failure to oral anti-diabetic agents
J Endocrinol Invest
State of diabetes care in the United States
Am J Manag Care
Executive summary: standards of medical care in diabetes—2009
Diabetes Care
Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49)
JAMA
Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report
Diabetes Care
Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002
Ann Intern Med
Is glycemic control improving in U.S. adults?
Diabetes Care
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
N Engl J Med
Effects of intensive glucose lowering in type 2 diabetes
N Engl J Med
Weight changes following the initiation of new anti-hyperglycemic therapies
Diabetes Obes Metab
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
J Clin Endocrinol Metab
Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients
Diabetes
Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake
Eur J Endocrinol
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
J Clin Invest
Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes
Diabetes
Overview of 6 years' therapy of type II diabetes: a progress disease (UKPDS 16)
Diabetes
β-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis
J Clin Endocrinol Metab
Reduced incretin effect in type 2 (non-insulin-dependent) diabetes
Diabetologia
10-Year follow-up of intensive glucose control in type 2 diabetes
N Engl J Med
Long-term follow-up after tight control of blood pressure in type 2 diabetes
N Engl J Med
Position statement: standards of medical care in diabetes—2007
Diabetes Care
Road maps to achieve glycemic control in type 2 diabetes mellitus
Endocr Pract
Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada
Can J Diabetes
Diabetes translation: a blueprint for the future
Diabetes Care
Staged diabetes management: toward an integrated model of diabetes care
Diabetes Care
Reducing lower extremity amputation due to diabetes: application of staged diabetes management approach in a primary care setting
J Fam Pract
Systematic implementation of customized guidelines: the staged diabetes management approach
J Clin Outcomes Manag
Disease management for diabetes mellitus: impact on hemoglobin A1c
Am J Manag Care
Cited by (0)
Statement of author disclosure: Please see the Author Disclosures section at the end of this article.